Transplant recipients show a high incidence of infections, often with atypical manifestations mainly because of drug-related immunosuppression. Mycobacterial infections can be life-threatening in immunosuppressed patients due to the risk of dissemination. There have been only few reports of cutaneous infections with Mycobacterium abscessus among immunosuppressed patients. We present a rare case with a sporotrichoid skin infection with M. abscessus in a renal recipient. The value of immunohistochemical detection of mycobacteria using an anti-BCG antibody in the diagnostic work-up skin biopsies is demonstrated. Long-term antibiotic treatment resulted in complete remission, although recurrences with atypical presentation were observed.

Schafer U, Nilles M, Schill WB, Schutterle G: Atypical mycobacteriosis in immunosuppression. Hautarzt 1993;44:106–109.
Kutzner H, Argenyi ZB, Requena L, Rutten A, Hugel H: A new application of BCG antibody for rapid screening of various tissue microorganisms. J Am Acad Dermatol 1998;38:56–60.
Moore M, Frerichs JB: An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region: Report of a case with a study of the organism, Mycobacterium abscessus, n. sp. J Invest Dermatol 1953;20:133–169.
Cooper JF, Lichtenstein MJ, Graham BS, Schaffner W: Mycobacterium chelonae: A cause of nodular skin lesions with a proclivity for renal transplant recipients. Am J Med 1989;86:173–177.
Palenque E: Skin disease and nontuberculous atypical mycobacteria. Int J Dermatol 2000;39:659–666.
Inman PM, Beck A, Brown AE, Stanford JL: Outbreak of injection abscesses due to Mycobacterium abscessus. Arch Dermatol 1969;100:141–147.
Camargo D, Saad C, Ruiz F, Ramirez ME, Lineros M, Rodriguez G, Navarro E, Pulido B, Orozco LC: Iatrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect 1996;117:113–119.
Wallace RJ Jr, Brown BA, Onyi GO: Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: Importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992;166:405–412.
Lee WJ, Kim TW, Shur KB, Kim BJ, Kook YH, Lee JH, Park JK: Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath. J Dermatol 2000;27:264–268.
Brunel P, Laurens G, Sebert JL, Labeille B, Schmit JL, Makdassi R, Fournier A: Cutaneous and articular infection by Mycobacterium chelonei in an immunodeficient patient. Ann Méd Interne (Paris) 1989;139:619–620.
Morris-Jones R, Fletcher C, Morris-Jones S, Brown T, Hilton RM, Hay R: Mycobacterium abscessus: A cutaneous infection in a patient on renal replacement therapy. Clin Exp Dermatol 2001;26:415–418.
Murdoch ME, Leigh IM: Sporotrichoid spread of cutaneous Mycobacterium chelonei infection. Clin Exp Dermatol 1989;14:309–312.
Rodriguez G, Ortegon M, Camargo D, Orozco LC: Iatrogenic Mycobacteriumabscessus infection: Histopathology of 71 patients. Br J Dermatol 1997;137:214–218.
Fitzgerald DA, Smith AG, Lees A, Yee L, Cooper N, Harris SC, Gibson JA: Cutaneous infection with Mycobacterium abscessus. Br J Dermatol 1995;132:800–804.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.